Compugen Discloses Experimental Results for Novel Checkpoint Candidate for Cancer Immunotherapy & Discovery of Two New Candid...
16 Junio 2014 - 6:00AM
Business Wire
CGEN-15052 shown to inhibit T cell
activation and to be expressed in multiple cancers including high
expression in lung cancer tissues
Predictive discovery of two new checkpoint
candidates increases to eleven the number discovered by the
Company
Compugen Ltd. (NASDAQ: CGEN) disclosed today positive
experimental results for CGEN-15052, a novel immune checkpoint
candidate for cancer immunotherapy, which in several experimental
settings demonstrated robust inhibition of T cell activation, both
as a membrane protein and as an Fc fusion protein. Initial testing
of human cancer tissue samples with a polyclonal antibody indicated
that CGEN-15052 is expressed in multiple epithelial cancers, with
particularly high expression in lung cancer samples. These positive
findings support CGEN-15052’s involvement in tumor immunology and
its potential as a target for cancer immunotherapy.
Compugen also disclosed today the predictive discovery of two
new B7-like immune checkpoint candidates, increasing to eleven the
total number of such candidates discovered to date by the Company
in this area of high medical and pharmaceutical industry interest.
The predictive discovery of these two new immune checkpoint
candidates was accomplished utilizing the same predictive models
and algorithms that led to the identification of nine novel
candidates in the Company’s earlier discovery efforts, but followed
enhancement of these models and algorithms through incorporation of
additional information obtained from those initial efforts.
Dr. Anat Cohen Dayag, Compugen’s President and CEO, stated, “Our
disclosures today of successful experimental results for another of
our initial nine checkpoint discoveries, and of new discoveries
from a follow-on run utilizing the same predictive models, but
enhanced with information from such initial discovery efforts,
provide excellent validation of the value and uniqueness of our
predictive discovery capabilities. After more than a decade of
extensive multidisciplinary research to gain deeper understanding
of key biological phenomena, providing the basis for the creation
of our predictive models and discovery platforms, it is very
rewarding to see these promising results from our first focused use
of this powerful capability.”
About Immune Checkpoints
Immune checkpoints are inhibitory receptors and their ligands,
which are crucial for the maintenance of self-tolerance (that is,
the prevention of autoimmunity) and for the protection of tissues
from damage when the immune system is responding to pathogenic
infection or other injuries. These immune checkpoints, which are
"highjacked" by tumors to block the ability of the immune system to
destroy the tumor (immune resistance), have lately emerged as "game
changers" and promising targets for cancer immunotherapy.
Therapeutic blockade of immune checkpoints can boost anti-tumor
immunity, enabling the patient’s immune system to recognize and
attack the tumor cells, and mount durable anti-tumor responses and
tumor destruction. The blockade of immune checkpoints unleashes the
potential of the anti-tumor immune response in a fashion that is
transforming cancer therapeutics. Checkpoint-blocking antibodies
have lately demonstrated impressive clinical benefits and long-term
survival, even for end-stage patients, raising hopes that this
novel approach will lead to effective therapeutic strategies and
valuable additions in the fight against cancer.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of product candidates at
various stages from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco is developing oncology
and immunology monoclonal antibody therapeutic candidates against
its drug targets. For additional information, please visit
Compugen's corporate website at http://www.cgen.com/.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the potential of CGEN-15052
for cancer immunotherapy. Forward-looking statements can be
identified by the use of terminology such as “will,” “may,”
“expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with
collaborators; the inability to reach mutually agreeable terms and
conditions with respect to potential new collaborations; the impact
of competitive products and technological changes; risks relating
to the development of new products; and the ability to implement
technological improvements. These and other factors are discussed
in the "Risk Factors" section of Compugen’s most recent Annual
Report on Form 20-F as filed with the Securities and Exchange
Commission as well as other documents that may be subsequently
filed by Compugen from time to time with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
